An Emerging Cause of Treatable Encephalitis: A Case of Anti-NMDA receptor (NMDAR) Encephalitis

Authors

  • Praveen Kumar Yadav Consultant Neurologist and in-charge, Department of Neuro-Medicine, The Mission Hospital, Durgapur, West Bengal, India
  • Dipanwita Sen Consultant and Head of Department of Obstrectics and Gynecology, The Mission Hospital, Durgapur, West Bengal, India

DOI:

https://doi.org/10.37591/rrjon.v7i3.156

Abstract

Anti-NMDA Receptor encephalitis is the most common type of autoimmune limbic encephalitis known. It is characterised by sub-acute onset of psychiatric symptoms along with refractory epilepsy, orofacial and limb dyskinesia and dysautonomia. High clinical suspicion and appropriate antibody testing in cerebrospinal fluid (CSF) and serum is required for early diagnosis and initiation of immunotherapy. Delay in treatment may lead to significant permanent neuro-deficits as well as mortality. Here, we present a case of 20-year-old female who presented with hallmark clinical features and high titre NMDAR antibody positivity in serum and CSF. She failed to respond with first line immunosuppressant (combination of immunoglobulin and steroids) and had to be started on weekly Rituximab for a month with dramatic clinical response. She was continued on oral steroids for 6 months and Azathioprine for 1 year. USS Pelvis and MRI Pelvis did not reveal any ovarian teratoma even after two and half years of regular follow up with 6 monthly ultrasound scan of the pelvis. This case highlights that we should diagnose the illness early and initiates second line treatment like Rituximab in case of failure to respond to first line agents in initial ten days.


Keywords: NMDAR, Encephalitis, Rituximab, Teratoma, Seizures

Cite this Article
Praveen Kumar Yadav, Dipanwita Sen. An Emerging Cause of Treatable Encephalitis: A Case of Anti-NMDA Receptor (NMDAR) Encephalitis. Research and Reviews: Journal of Neuroscience. 2017; 7(3): 8–11p.


Downloads

Published

2018-03-20

Issue

Vol. 7 No. 3 (2017)

Section

Articles

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.